Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Alligator Bioscience. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Alligator Bioscience's earnings available for a low price, and how does
this compare to other companies in the same industry?
Alligator Bioscience is not considered high growth as it is expected to be loss making for the next 1-3 years.
Alligator Bioscience's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Alligator Bioscience's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Alligator Bioscience's finances.
The net worth of a company is the difference between its assets and liabilities.
Alligator Bioscience is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Alligator Bioscience's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Alligator Bioscience's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Alligator Bioscience has no debt, it does not need to be covered by short term assets.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Per Norlén has been the Chief Executive Officer at Alligator Bioscience AB (publ) since 2015 and served as its Chief Medical Officer from 2010 to January 2018 and was its Vice President of Development. Dr. Norlén has 10 years of drug development experience, from medic at phase I clinical pharmacology units, to design and interpretation within the pharmaceutical industry. Before joining Alligator Bioscience, Dr. Norlén was employed at AstraZeneca R&D for 4 years, as Senior Clinical Pharmacology Physician and Global Discipline Leader of Clinical Pharmacology Physicians, with responsibility for phase I/II clinical trials within respiratory and inflammation. Dr. Norlén is M.D., PhD, board certified specialist in Clinical Pharmacology and Associate Professor in Experimental.
Per's compensation has increased whilst company is loss making.
Per's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Alligator Bioscience management team is about average.
Chief Executive Officer
Interim Chief Financial Officer
Chief Operating Officer
Director of Investor Relations & Communications
Senior Vice President of Preclinical Development
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Alligator Bioscience board of directors is about average.
Board of Directors
Carl Arne Borrebäck
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Alligator Bioscience individual insiders in the past 3 months, but not in substantial volumes.
Alligator Bioscience AB (publ) develops antibody-based pharmaceuticals for cancer treatment. It develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and bispecific fusion format for the development of novel dual-action antibodies. The company develops ADC-1013, an immunostimulatory antibody, which is in Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1015, a tumor-localizing bispecific CTLA-4 and OX40 antibody, which is in Phase I clinical trial for tumor-directed treatment of metastatic cancer. Its drug candidates in preclinical development stage include ATOR-1017, an immunostimulatory antibody that binds to the costimulatory receptor 4-1BB (CD137) in tumor-specific T cells; ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of metastatic cancer; and ATOR-1144, a bispecific antibody for treating solid tumors and hematologic malignancies. The company, through its subsidiary, Atlas Therapeutics AB, also holds a stake in Biosynergy (AC101), a preclinical project. It has operations in the United States, Sweden, Asia, and internationally. The company has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a license agreement with Janssen Biotech, Inc. for developing ADC-1013. Alligator Bioscience AB (publ) was founded in 2001 and is headquartered in Lund, Sweden.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.